Physician profile
Linda Andreassi
NPI 1477103323
$3,964.67
in general payments reported to CMS, 2019-2025
16 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $1,130 · 2023: $430 · 2024: $1,242 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,141.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,203.96 | 2021-2025 | |
| Janssen Biotech, INC. | $291.07 | 2024 | Stelara, Tremfya |
| Boston Scientific Corporation | $267.67 | 2024 | Orca, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $227.97 | 2023-2025 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $141.40 | 2025 | Rezdiffra |
| Atricure, INC. | $129.68 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $128.35 | 2024 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $119.92 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $101.52 | 2022 | |
| Gilead Sciences, INC. | $91.97 | 2021 | |
| Amgen INC. | $87.86 | 2025 | Uplizna |
| Astrazeneca Pharmaceuticals LP | $64.58 | 2023 | Andexxa |
| Exact Sciences Corporation | $64.19 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Olympus America INC. | $15.37 | 2023 | Endoclot Phs |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Andreassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.